Culture Biosciences

culturebiosciences.com →

-54%

est. 2Y upside i

HealthcareSeries C

We grow cells for biotech companies.

Rank

#2451

Sector

Biotechnology

Est. Liquidity

~4Y

Data Quality

Data: Low

Culture Biosciences operates in a high-growth sector with a differentiated 'biomanufacturing-as-a-service' model and strong market position, evidenced by its Series C funding to accelerate commercial growth.

Last updated: March 10, 2026

Bull (25%)+150%

Culture Biosciences' Stratyx 250 and AI-powered Console platform achieve significant market penetration, capturing substantial share in the rapidly growing next-generation biomanufacturing and bioprocess automation markets. Strategic partnerships and product differentiation lead to accelerated revenue growth, reaching an estimated $200M+ ARR by 2028 and justifying a $1.25B valuation, a 2.5x increase from the assumed current valuation.

Base (50%)+25%

The company continues to grow steadily, expanding its customer base and refining its 'biomanufacturing-as-a-service' model. It maintains its competitive position against existing players, achieving moderate revenue growth to an estimated $100M ARR by 2028, leading to a valuation of $625M, a 1.25x increase from the assumed current valuation.

Bear (25%)-50%

Dominant incumbents or well-funded competitors launch directly competing cloud-based bioreactor platforms, eroding Culture Biosciences' market share and pricing power. High capital intensity and regulatory hurdles slow expansion, leading to slower-than-expected revenue growth and a down round or acquisition at a reduced valuation of $250M, resulting in a significant loss for common stock holders given the preference stack.

Est. time to liquidity~4.0 years

Preference Stack Risk

high

With total funding of $107M and an assumed current valuation of $500M, investors hold approximately $107M in liquidation preferences, representing 21.4% of the company's assumed value.

Dilution Risk

moderate

As a Series C company in a capital-intensive sector, further funding rounds are likely before an exit, posing a moderate risk of additional dilution for existing equity holders.

Secondary Liquidity

none

There is no indication of active secondary markets or tender offers for Culture Biosciences' shares at this stage.

Other — 5 roles

View all 5 open roles at Culture Biosciences →

Last updated: March 10, 2026

Questions to Ask at the Interview

Strategic questions based on Culture Biosciences's data — designed to show you've done your homework.

  • 1

    “Given the undisclosed Series C valuation and the high capital intensity of the business, how does Culture Biosciences plan to manage future funding needs and potential dilution for employees?”

  • 2

    “With large incumbents like Thermo Fisher Scientific and Danaher operating in adjacent spaces, what specific strategies is Culture Biosciences employing to maintain and expand its competitive moat, particularly concerning the Stratyx 250 and Console platform?”

  • 3

    “The bioprocess automation market is growing. How does Culture Biosciences prioritize its product roadmap (e.g., new hardware, AI software features, service offerings) to maximize market penetration and address the most pressing needs of its target customers over the next 2-3 years?”

Community

Valuation Sentiment

Our model estimates -54% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.